335 related articles for article (PubMed ID: 18083272)
21. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
22. Improvement of psoriatic onychodystrophy by a water-soluble nail lacquer.
Cantoresi F; Sorgi P; Arcese A; Bidoli A; Bruni F; Carnevale C; Calvieri S
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):832-4. PubMed ID: 19470045
[TBL] [Abstract][Full Text] [Related]
23. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
24. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
26. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
[TBL] [Abstract][Full Text] [Related]
27. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA; Kalb RE
J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
[TBL] [Abstract][Full Text] [Related]
28. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
[TBL] [Abstract][Full Text] [Related]
29. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients.
Fabroni C; Gori A; Troiano M; Prignano F; Lotti T
J Eur Acad Dermatol Venereol; 2011 May; 25(5):549-53. PubMed ID: 20707829
[TBL] [Abstract][Full Text] [Related]
30. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
31. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis.
Bardazzi F; Antonucci VA; Tengattini V; Odorici G; Balestri R; Patrizi A
J Dtsch Dermatol Ges; 2013 Nov; 11(11):1065-70. PubMed ID: 24119121
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the efficacy of acitretin therapy for nail psoriasis.
Tosti A; Ricotti C; Romanelli P; Cameli N; Piraccini BM
Arch Dermatol; 2009 Mar; 145(3):269-71. PubMed ID: 19289755
[TBL] [Abstract][Full Text] [Related]
33. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.
Gümüşel M; Özdemir M; Mevlitoğlu I; Bodur S
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1080-4. PubMed ID: 21118309
[TBL] [Abstract][Full Text] [Related]
35. Treatment of nail psoriasis with a modified regimen of steroid injections.
Saleem K; Azim W
J Coll Physicians Surg Pak; 2008 Feb; 18(2):78-81. PubMed ID: 18454890
[TBL] [Abstract][Full Text] [Related]
36. Nail psoriasis and biologics.
Noiles K; Vender R
J Cutan Med Surg; 2009; 13(1):1-5. PubMed ID: 19298765
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
38. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
40. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]